Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-05-24Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial evaluating a multi-modality approach combining Yttrium-90 ibritumomab tiuxetan, fludarabine, radiation therapy, and d…
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab in patients undergoing donor peripheral blood stem cell transplantation for relapsed or refractory B-cell…
-
CLINICAL_TRIALS trial_result · 2017-05-19Clinical Trial Update: Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma [Phase 4]
A Phase 4 trial comparing two doses of temsirolimus (Torisel) in patients with mantle cell lymphoma/non-Hodgkin's lymphoma has completed wit…
-
CLINICAL_TRIALS trial_result · 2017-05-17Clinical Trial Update: Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer [Phase 2]
Phase 2 trial evaluating haploidentical donor bone marrow transplantation in patients with high-risk hematologic cancers; results completed …
-
CLINICAL_TRIALS trial_result · 2017-05-12Clinical Trial Update: Safety and Tolerability of HSC835 in Patients With Hematological Malignancies [Phase 1, Phase 2]
Phase 1/2 trial assessing safety and tolerability of HSC835 in patients with various hematologic malignancies completed with results posted …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-05-10Clinical Trial Update: Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating bortezomib plus vorinostat as maintenance after autologous stem cell transplant in non-Hodgkin lymphoma showed resu…
-
CLINICAL_TRIALS trial_result · 2017-05-08Clinical Trial Update: Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial of oral clofarabine in relapsed/refractory non-Hodgkin lymphoma completed with posted results.
-
CLINICAL_TRIALS trial_result · 2017-05-04Clinical Trial Update: Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies [Phase 2, Phase 3]
A phase 2/3 trial evaluating non-myeloablative allogeneic HSCT from HLA-matched related or unrelated donors in low-grade B-cell malignancies…
-
CLINICAL_TRIALS trial_result · 2017-04-11Clinical Trial Update: Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies [Phase 1]
A Phase 1 clinical trial update reports the completion of a study evaluating intravenously administered SNS-032 in patients with advanced B-…
-
CLINICAL_TRIALS trial_result · 2017-04-07Clinical Trial Update: Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating lenalidomide plus rituximab in previously untreated mantle cell lymphoma; results have been posted.
-
CLINICAL_TRIALS trial_result · 2017-04-07Clinical Trial Update: Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL [Phase 1, Phase 2]
Phase I/II study evaluating Velcade (bortezomib) added to CHOP-Rituximab in untreated diffuse large B-cell lymphoma and mantle cell lymphoma…
-
CLINICAL_TRIALS withdrawal · 2017-04-05Clinical Trial Update: Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation [Phase 2]
This clinical trial update reports that the Phase 2 study of Sotrastaurin acetate for relapsed or refractory chronic lymphocytic leukemia, s…
-
CLINICAL_TRIALS trial_result · 2017-03-31Clinical Trial Update: Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [NA]
A terminated clinical trial evaluated mobilizing donor peripheral blood stem cells with plerixafor and filgrastim before donor transplant in…
-
CLINICAL_TRIALS research · 2017-03-16Clinical Trial Update: Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma [Phase 1, Phase 2]
This document describes a Phase 1/2 clinical trial evaluating competitive transfer of two αCD19-TCRz-CAR-T cell constructs (one with CD28 an…
-
CLINICAL_TRIALS trial_result · 2017-03-10Clinical Trial Update: Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients [Phase 1]
Phase 1 clinical trial update of an anti-CD22 CAR-T therapy for CD19-refractory or resistant lymphomas, including diffuse large B-cell lymph…
-
CLINICAL_TRIALS trial_result · 2017-03-09Clinical Trial Update: Tandem Auto-Allo Transplant for Lymphoma [Phase 2]
Phase 2 clinical trial update on tandem auto-allo transplantation for various lymphomas, with completed status and results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-03-09Clinical Trial Update: Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). [Phase 1, Phase 2]
A phase 1/2 study evaluating escalating doses of temsirolimus (Torisel) in combination with R-CHOP, R-FC, or R-DHA regimens in patients with…
-
CLINICAL_TRIALS trial_result · 2017-03-07Clinical Trial Update: Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL [Phase 3]
This clinical trial update reports on the efficacy and safety of the Rituximab-based R-HAD regimen alone or in combination with Bortezomib i…
-
CLINICAL_TRIALS research · 2017-03-07Clinical Trial Update: Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL [Phase 3]
Phase 3 trial evaluating induction regimens R-CHOP vs R-FC, followed by interferon maintenance versus rituximab maintenance in mantle cell l…
-
CLINICAL_TRIALS trial_result · 2017-03-01Clinical Trial Update: Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy [Phase 3]
Phase 3 trial comparing ibrutinib versus temsirolimus in relapsed/refractory mantle cell lymphoma; results completed with results posted in …
-
CLINICAL_TRIALS trial_result · 2017-02-28Clinical Trial Update: CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy [Phase 1]
Phase 1 trial evaluating CART19 therapy for B-cell hematologic malignancies including various lymphomas and leukemias that are refractory or…
-
CLINICAL_TRIALS trial_result · 2017-02-16Clinical Trial Update: Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy
This update notes the completion of an observational study evaluating patients with newly diagnosed Mantle Cell Lymphoma who are not eligibl…
-
CLINICAL_TRIALS trial_result · 2017-02-15Clinical Trial Update: CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant [Phase 1, Phase 2]
This update covers a phase 1/2 clinical trial evaluating CD19 CAR T cells for B-cell malignancies in patients after allogeneic transplantati…
-
CLINICAL_TRIALS trial_result · 2017-02-09Clinical Trial Update: AMG 319 Lymphoid Malignancy FIH [Phase 1]
First-in-human Phase 1 clinical trial update for AMG 319 in lymphoid malignancies, including chronic lymphocytic leukemia and various lympho…
-
CLINICAL_TRIALS trial_result · 2017-01-31Clinical Trial Update: Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma has completed with results posted.